SCREENING FOR INHIBITORS OF DIFFERENT KRAS MUTANTS, A KEY ONCOGENE IN NONSMALL-CELL LUNG CANCER

Abstract

Nonsmall-cell lung cancer is the most prevalent type of lung cancer accounting for 85% of all lung cancer cases. Ki-ras2 Kirsten rat sarcoma viral oncogene homolog(KRAS) belongs to the RAS family. KRAS is a common oncogenic signal transducer protein predominantly mutated in cancers at positions G12, G13, and Q61. In this study, we successfully knocked out the coding region(Exon 2) of KRAS in the H1299 cell line by CRISPR/Cas9 system. Overall 8 positive clones were detected from 128 individual colonies. The clonal subpopulations have shown various growth rates. Some clones showed higher growth rates, while others grew more slowly, due to the off-targeted effects of the CRISPR/Cas9 system. The deletion efficiency was proved by the Sanger sequencing analysis.